irinotecan has been researched along with Brain Neoplasms in 248 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (3.23) | 18.2507 |
| 2000's | 87 (35.08) | 29.6817 |
| 2010's | 136 (54.84) | 24.3611 |
| 2020's | 17 (6.85) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, JW; Jung, HA; Kong, DS; Lee, JI; Lee, MS; Lee, SH; Lee, YP; Nam, DH; Seol, HJ | 1 |
| Andre, N; Beccaria, K; Bertozzi, AI; Boddaert, N; Bourdeaut, F; Butel, T; Cuinet, A; De Carli, E; de Marcellus, C; Dufour, C; Figarella-Branger, D; Fouyssac, F; Grill, J; Leblond, P; Pasqualini, C; Puget, S; Robert, MP; Tauziède-Espariat, A; Valteau-Couanet, D; Varlet, P | 1 |
| Chen, X; Chen, Z; Tian, F | 1 |
| Biltekin, B; Cetin, A; Ozevren, H | 1 |
| Ballester, LY; Bhattacharjee, MB; Brown, RE; Buja, LM; Chen, L; Glass, WF; Hergenroeder, GW; Hunter, RL; Linendoll, N; Lu, G; Pilichowska, M; Pillai, AK; Rao, M; Tian, X; Wu, JK; Zhang, R; Zhu, JJ; Zhu, P | 1 |
| Abrey, LE; Aftab, DT; Cho, NS; Cloughesy, TF; Ellingson, BM; Garcia, J; Hagiwara, A; Harats, D; Hessel, C; Morris, CJ; Nathanson, DA; Oshima, S; Oughourlian, TC; Rachmilewitz Minei, T; Raymond, C; Sanvito, F; Telesca, D; Wen, PY | 1 |
| Mellinghoff, IK | 1 |
| Almond, L; Cruickshank, G; Daniel, S; Detta, A; Gawley, M; Hingtgen, S; Kaur, S; Lastakchi, S; McConville, C; Miller, R; Sheets, K | 1 |
| Golby, AJ; McDannold, N; Power, C; Reardon, DA; Sun, T; Supko, JG; Vykhodtseva, N; Zhang, Y | 1 |
| Di, F; Li, Q; Ma, HY; Sun, T; Xiang, RL; Xu, Y | 1 |
| Fioretzaki, RG; Kosmas, C; Papageorgiou, GI; Tsakatikas, SA | 1 |
| André, N; Appay, R; Gentet, JC; Padovani, L; Revon-Rivière, G; Roux, C; Saultier, P; Scavarda, D; Verschuur, A | 1 |
| Baekey, J; Carcieri, A; Cielo, D; Disano, D; Donnelly, J; Elinzano, H; MacKinnon, K; Mohler, A; Robison, J; Safran, H; Sturtevant, A; Toms, S; Vatketich, J; Wood, R | 1 |
| Cabrales, P; Oronsky, B; Reid, T | 1 |
| Chen, SM; Liu, SJ; Lo, WL; Tang, YL; Tseng, YY; Yang, TC | 1 |
| Beberok, A; Maszczyk, M; Rok, J; Rzepka, Z; Wrześniok, D | 1 |
| Fioretzaki, R; Kosmas, C; Papageorgiou, G; Tsakatikas, S | 1 |
| Gao, Z; Hui, Y; Ma, X; Ren, S; Wang, Y | 1 |
| He, Z; Jie, M; Li, HF; Lin, JM; Liu, H; Mao, S | 1 |
| DeLuca, JG; Herman, JA; Lee, E; Paddison, P; Pain, M; Toledo, CM; Wang, H; Yong, RL; Zhu, J | 1 |
| Belka, C; Friedrich, F; Glas, M; Goldbrunner, R; Grau, S; Grauer, O; Hänel, M; Hau, P; Herrlinger, U; Kebir, S; Krex, D; Leutgeb, B; Mack, F; Nießen, M; Proescholdt, M; Ringel, F; Rohde, V; Ronellenfitsch, MW; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schnell, O; Steinbach, JP; Stummer, W; Tabatabai, G; Tzaridis, T; Uhl, M; Urbach, H; Vajkoczy, P; Weyerbrock, A | 1 |
| Neil, D | 1 |
| Adkins, CE; Dolan, EL; Griffith, JI; Hendriks, BS; Lee, H; Lockman, PR; Mohammad, AS; Sechrest, E; Shah, N; Terrell-Hall, TB | 1 |
| Hu, T; Li, Q; Liu, C; Ma, Y; Wu, G; Xiong, J; Zhao, Y | 1 |
| Cloughesy, TF; Lee, EQ; McFaline-Figueroa, JR; Wen, PY | 1 |
| Ashley, D; Bigner, D; Keir, ST; Landi, D; Thompson, EM | 1 |
| Ameratunga, M; Grant, R; Khasraw, M; Pavlakis, N; Simes, J; Wheeler, H | 1 |
| Bobiak, S; Dastani, H; Kim Le, T; Korytowsky, B; Norden, AD; Singh, P; You, M | 1 |
| Cai, J; Chen, Q; Dong, J; Jiang, C; Li, S; Meng, X; Shi, L | 1 |
| Bähr, O; Belka, C; Borchers, C; Galldiks, N; Gerlach, R; Glas, M; Goldbrunner, R; Hänel, M; Hattingen, E; Hau, P; Herrlinger, U; Junold, N; Kebir, S; Krex, D; Mack, F; Proescholdt, M; Rohde, V; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schmidt-Graf, F; Seidel, C; Steinbach, JP; Tabatabai, G; Tzaridis, T; Vatter, H; Weller, J; Weyerbrock, A | 1 |
| Ashley, D; Breazna, A; Cisar, L; Clausen, N; Cruz-Martinez, O; Dorman, A; Elliott, M; English, M; Frappaz, D; Fuster, JL; Geoerger, B; Gesner, L; Grill, J; Hargrave, D; Icher, C; Leblond, P; Perilongo, G; Pietsch, T; Rialland, X | 1 |
| Albares, MP; del Carmen Leiva-Salinas, M; Frances, L; Guijarro, J; Ramon, R | 1 |
| Bauer, D; Biassoni, V; Casanova, M; Catania, S; De Pava, MV; Gandola, L; Indini, A; Massimino, M; Modena, P; Pecori, E; Podda, M; Polastri, D; Rampini, P; Schiavello, E | 1 |
| Cripe, T; Geller, J; Nagarajan, R; Turpin, B; Wagner, L; Weiss, B | 1 |
| Barboriak, DP; Bokstein, F; Boxerman, JL; Gilbert, MR; McKinstry, RC; Ratai, EM; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
| Ahn, HS; Kang, HJ; Kim, H; Lee, JW; Park, JD; Park, KD; Shin, HY | 1 |
| Autran, D; Barrie, M; Boucard, C; Chinot, O; Loundou, A; Matta, M; Tabouret, E; Thiebaut, A | 1 |
| Blaum, M; Galldiks, N; Heinzel, A; Langen, KJ; Mottaghy, FM; Müller, D; Verburg, FA | 1 |
| Barboriak, DP; Boxerman, JL; Chi, TL; Gilbert, MR; Jain, R; Larvie, M; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
| Blasius, E; Boström, J; Glas, M; Greschus, S; Herrlinger, U; Kebir, S; Landwehr, C; Mack, F; Rasch, K; Schäfer, N; Schaub, C; Scheffler, B; Seifert, M; Simon, M; Stuplich, M; Urbach, H; Vilz, B; Waha, A | 1 |
| Honda, R; Inoue, S; Nagashima, K; Ohsaki, Y; Onodera, H; Tanno, S | 1 |
| Banerjee, A; Boyett, JM; Fangusaro, J; Fouladi, M; Friedman, HS; Gajjar, A; Gilbertson, RJ; Goldman, S; Gururangan, S; Jakacki, R; Kun, LE; McLendon, RE; Onar-Thomas, A; Packer, RJ; Pollack, IF; Poussaint, TY; Warren, KE; Wu, S | 1 |
| Aboody, KS; Abramyants, Y; Barish, ME; Brown, CE; Ghoda, LY; Gilchrist, M; Gutova, M; Lacey, SF; Metz, MZ; Najbauer, J; Portnow, J; Potter, PM; Synold, TW; Tirughana, R; Vo, T | 1 |
| Banerjee, A; Boyett, JM; Fahey, F; Fangusaro, J; Fouladi, M; Friedman, HS; Gajjar, A; Gilbertson, RJ; Goldman, S; Gururangan, S; Jakacki, R; Kun, LE; McLendon, RE; Onar-Thomas, A; Packer, RJ; Pollack, IF; Poussaint, TY; Vajapeyam, S; Wu, S | 1 |
| Bautista, F; Dufour, C; Geoerger, B; Grill, J; Lacroix, L; Minard-Colin, V; Paci, A; Valteau-Couanet, D; Varlet, P | 1 |
| Abbasi, T; Bharati, IS; Chao, Y; Cong, X; Fogal, V; Gallagher, M; Jiang, P; Kesari, S; Makale, M; Mukthavaram, R; Mukthavavam, R; Nomura, N; Pastorino, S; Pingle, SC; Vali, S | 1 |
| Ask, A; Costa, JC; Engelholm, S; Grunnet, K; Hansen, S; Hofland, KF; Kristiansen, C; Lassen, U; Muhic, A; Poulsen, HS; Schultz, HP; Sorensen, M; Thomsen, C | 1 |
| Bankiewicz, KS; Berger, MS; Beyer, J; Drummond, DC; Forsayeth, J; Hadaczek, P; Hayes, ME; Kirpotin, DB; Krauze, MT; Noble, CO; Park, JW | 1 |
| Cloughesy, TF; Dahlbom, M; Huang, SC; Phelps, ME; Schiepers, C; Wardak, M | 1 |
| Anghileri, E; Aquino, D; Bruzzone, MG; Cuppini, L; Di Stefano, AL; Eoli, M; Finocchiaro, G; Scotti, A | 1 |
| Egle, A; Greil, R; Grundbichler, M; Hufnagl, C; Magnes, T; Melchardt, T; Moik, M; Strasser, M; Weiss, L | 1 |
| Bonnetain, F; Campello, C; Castera, D; Chauffert, B; Chinot, O; Dalban, C; Durando, X; Fabbro, M; Feuvret, L; Frappaz, D; Frenay, M; Ghiringhelli, F; Guillamo, JS; Honnorat, J; Schott, R; Skrzypski, J; Taillandier, L; Taillia, H; Tennevet, I | 1 |
| Boisselier, B; Chinot, O; Delattre, JY; Di Stefano, AL; Ducray, F; Farina, P; Figarella-Branger, D; Gallego Perez-Larraya, J; Honnorat, J; Idbaih, A; Laffaire, J; Marie, Y; Sanson, M; Vintonenko, N | 1 |
| Rovere, RK | 1 |
| Kjaer, A; Kristoffersen, K; Lassen, U; Madsen, J; Michaelsen, SR; Nedergaard, MK; Poulsen, HS; Stockhausen, MT | 1 |
| Hongeng, S; Manaspon, C; Nasongkla, N; Nittayacharn, P | 1 |
| Abramson, V; Anders, C; Berg, J; Carey, LA; Carpenter, JT; Deal, AM; Karginova, O; Kelly Marcom, P; Lin, NU; Liu, MC; Melhem-Bertrandt, A; Melisko, M; Nanda, R; Parker, J; Perou, CM; Peterman, A; Prat, A; Puhalla, S; Smith, JK; Stearns, V; Storniolo, AM; Van Poznak, C; Winer, EP; Wolff, AC | 1 |
| Corbacioglu, S; Debatin, KM; Engelke, J; Fulda, S; Halatsch, ME; Karpel-Massler, G; Nonnenmacher, L; Simmet, T; Westhoff, MA | 1 |
| Ameratunga, MS; Grant, R; Khasraw, M; Pavlakis, N; Wheeler, H | 1 |
| Chow, L; DeWire, M; Fouladi, M; Goldman, S; Hummel, T; Lane, A; Leach, J; Miles, L; Salloum, R; Stevenson, C; Sutton, M | 1 |
| Calkins, SM; Cinar, P; Kelley, RK; Venook, AP | 1 |
| Alexandru-Abrams, D; Bota, DA; Hsu, FP; Paff, M | 1 |
| Barboriak, DP; Boxerman, JL; Gilbert, MR; Prah, M; Schmainda, KM; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
| Cho, JM; Go, SI; Jeon, KN; Kang, JH; Kang, MH; Kim, HG; Kim, MJ; Lee, A; Lee, GW; Lee, JH; Lee, US; Lee, WS | 1 |
| Adachi, S; Arakawa, Y; Heike, T; Hiramatsu, H; Mizowaki, T; Nishiuchi, R; Saida, S; Shibata, H; Umeda, K; Watanabe, K | 1 |
| Gil-Ranedo, J; Mendiburu-Eliçabe, M | 1 |
| Chen, TC; Golden, EB; Gong, A; Hofman, FM; Howard, A; Jhaveri, N; Louie, SG; Schönthal, AH; Sivakumar, W; Torres, S; Vaikari, VP; Wang, W | 1 |
| Beccaria, K; Carpentier, A; Farinotti, R; Fernandez, C; Goldwirt, L; Idbaih, A; Labussiere, M; Levasseur, C; Milane, A; Schmitt, C | 1 |
| Ames, MM; Berg, AK; Buckner, JC; Galanis, E; Jaeckle, KA; Reid, JM | 1 |
| Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; Lou, E; McSherry, F; Miller, E; Peters, KB; Reardon, DA; Vredenburgh, JJ | 1 |
| Dalla Pozza, L; Heath, JA; Kalra, M; Kellie, SJ; McCowage, GB; Stevens, MM; Swamy, S | 1 |
| Boongird, A; Hongeng, S; Israsena, N; Larbcharoensub, N; Manaspon, C; Nasongkla, N; Vejjasilpa, K | 1 |
| Chang, TM; Kau, YC; Liu, SJ; Su, CH; Tseng, YY; Wang, YC; Yang, TC | 1 |
| Almeida, DS; Caeiro, C; Carvalho, BF; Castro, L; Costa, A; Damasceno, M; Fernandes, AC; Linhares, P; Osório, L; Sampaio, LV; Vaz, RC | 1 |
| Kanamori, M; Kawashima, R; Mano, Y; Saito, R; Sonoda, Y; Sumiyoshi, A; Tominaga, T; Zhang, R | 1 |
| Kimura, T; Matsuzaki, S; Ogita, K; Sawada, M; Ueda, Y; Yoshida, S; Yoshino, K | 1 |
| Adamson, C; Agarwal, VJ; Babu, R; Britt, D; Friedman, AH; Grossi, PM; Iyer, A; Karikari, IO; Komisarow, JM; Rahimpour, S; Thomas, S | 1 |
| Adkins, CE; Eldon, MA; Hoch, U; Hye, T; Lockman, PR; Mohammad, AS; Mohan, NK; Nounou, MI; Terrell-Hall, T | 1 |
| Anantha, M; Backstrom, I; Bally, MB; Chu, F; Kalra, J; Masin, D; Strutt, D; Verreault, M; Walker, D; Waterhouse, D; Wehbe, M; Yapp, DT | 1 |
| Balañá, C; Benavides, M; Fleitas, T; Gallego, O; Gil-Gil, M; Martínez-Sales, V; Palomero, I; Pérez-Segura, P; Reche, E; Reynés, G; Vaz, MA; Vila, V | 1 |
| Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M | 1 |
| Blumenthal, DT; Bokstein, F; Mendel, L | 1 |
| Broholm, H; Christensen, IJ; Dahlrot, RH; Grunnet, K; Hansen, S; Kosteljanetz, M; Larsen, VA; Lassen, U; Michaelsen, SR; Poulsen, HS; Toft, A; Urup, T | 1 |
| Al-Ghafari, AB; Carrier, DJ; Coyle, B; Hussein, D; Kerr, ID; Punjaruk, W; Storer, LC | 1 |
| Bähr, O; Banat, M; Filmann, N; Fimmers, R; Franz, K; Glas, M; Herrlinger, U; Kebir, S; Mack, F; Mittelbronn, M; Rieger, J; Schäfer, N; Schaub, C; Steinbach, JP; Thiepold, AL; Tichy, J; Waha, A | 1 |
| Anota, A; Bonnetain, F; Campello, C; Castera, D; Chauffert, B; Chinot, O; Dabakuyo, S; Dalban, C; Ducray, F; Durando, X; Fabbro, M; Feuvret, L; Frappaz, D; Frenay, M; Ghiringhelli, F; Guillamo, JS; Paquette, B; Schott, R; Skrzypski, J; Taillandier, L; Taillia, H; Tennevet, I; Vernerey, D | 1 |
| Ahle, G; Antoni, D; Atlani, D; Chaussemy, D; Clavier, JB; Couchot, J; Gaultier, C; Haoming, QC; Jastaniah, Z; Noël, G; Schott, R; Srour, R | 1 |
| Astorgues-Xerri, L; Bekradda, M; Berenguer-Daizé, C; Cayol, M; Cvitkovic, E; Lokiec, F; MacKenzie, S; Noel, K; Odore, E; Ouafik, L; Rezai, K; Riveiro, ME | 1 |
| Huang, YC; Lee, WH; Liu, SC; Liu, SJ; Su, CH; Tseng, YY; Wang, YC; Yang, ST | 1 |
| Boongird, A; Chaimongkolnukul, K; Hongeng, S; Kengkoom, K; Manaspon, C; Nasongkla, N; Nittayacharn, P; Vejjasilpa, K | 1 |
| Abrey, LE; Aftab, DT; Cloughesy, TF; Ellingson, BM; Harris, RJ; Hessel, C; Lai, A; Leu, K; Mason, WP; Nghiemphu, PL; Pope, WB; Sahebjam, S; Schwab, GM; Wen, PY; Woodworth, DC; Zaw, O | 1 |
| Barrie, M; Boucard, C; Campello, C; Chinot, O; Farina, P; Girard, N; Graillon, T; Lehmann, P; Petrirena, G; Tabouret, E | 1 |
| Fukai, H; Ichikawa, G; Kita, E; Kuwana, Y; Matsumoto, H; Nakayama, Y; Ohta, Y; Takami, M; Takimoto, T; Yamamoto, T | 1 |
| Ahmad, A; Ali, SA; Bejjani, G; Braffet, M; Friedland, DM; McHayleh, WM; Rahman, M; Sehgal, R | 1 |
| Armstrong, MB; Castle, VP; Mody, R; Opipari, AW; Schumacher, KR; Yanik, GA | 1 |
| Desjardins, A; Friedman, HS; Reardon, DA; Vredenburgh, JJ | 1 |
| Drappatz, J; Norden, AD; Wen, PY | 1 |
| Anderson, J; Doyle, T; Ellika, S; Jain, R; Mikkelsen, T; Schultz, L; Torcuator, R; Zuniga, RM | 1 |
| Bailey, L; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; Quinn, JA; Reardon, DA; Rich, JN; Sampson, J; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Grunnet, K; Hasselbalch, B; Kosteljanetz, M; Lassen, U; Nelausen, K; Olsen, P; Poulsen, HS; Sorensen, M | 1 |
| Ames, MM; Buckner, JC; Felten, SJ; Galanis, E; Jaeckle, KA; Nikcevich, DA; Reid, JM; Santisteban, M; Scheithauer, BW; Wiesenfeld, M; Wu, W | 1 |
| Albert, PS; Butman, JA; Camphausen, K; Duic, P; Fine, HA; Garren, N; Kim, L; Kreisl, TN; Mackey, M; Moore, K; Park, J; Royce, C; Stroud, I | 1 |
| Cohen, B; Fisher, MJ; Horn, M; Jakacki, R; MacDonald, T; Packer, RJ; Rood, B; Vezina, G | 1 |
| Dehais, C; Laigle-Donadey, F; Mazeron, JJ; Sanson, M | 1 |
| Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Bellanger, A; Carpentier, C; Dehais, C; Delattre, JY; Granger, B; Guillevin, R; Hoang-Xuan, K; Laigle-Donadey, F; Marie, Y; Meng, Y; Mokhtari, K; Psimaras, D; Rousseau, A; Sanson, M; Sierra del Rio, M; Taillibert, S; Vincent, LA | 1 |
| Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Abrey, LE; Cloughesy, T; Friedman, HS; Huang, J; Jensen, R; Mikkelsen, T; Nicholas, MK; Paleologos, N; Prados, MD; Schiff, D; Vredenburgh, J; Wen, PY; Yung, WK; Zheng, M | 1 |
| Baltas, D; Chatzisotiriou, A; Fountzilas, G; Fragkoulidi, A; Iliadis, G; Kalogera-Fountzila, A; Misailidou, D; Selviaridis, P; Tselis, N; Zamboglou, N | 1 |
| Batchelor, TT; Frosch, MP; Gerstner, ER | 1 |
| Ames, MM; Arusell, R; Ballman, KV; Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Hammack, JE; Jaeckle, KA; McGovern, RM; Morton, RF; Nikcevich, DA; Reid, JM; Safgren, SL; Schomberg, PJ; Uhm, JH; Wender, DB | 1 |
| Chamberlain, MC | 3 |
| Ishikawa, E; Kamiyama, H; Mashiko, R; Matsumura, A; Osuka, S; Takano, S | 1 |
| Kenmotsu, H; Koga, Y; Kuratsu, J; Kuroda, J; Matsumura, Y; Sugino, T; Yasunaga, M | 1 |
| Chinnaiyan, P; Kahali, S; Sarcar, B | 1 |
| Anderson, J; Doyle, T; Jain, R; Mikkelsen, T; Schultz, L; Torcuator, R; Zuniga, RM | 1 |
| Baltes, S; Brinker, T; Freund, I; Lewis, AL; Nolte, I | 1 |
| Kitamura, H; Masumori, N; Matsuda, Y; Sato, S; Takahashi, S; Tanaka, T; Tsukamoto, T | 1 |
| Cho, EK; Jung, SH; Kim, YS; Kyung, SY; Lee, JH; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB; Sym, SJ | 1 |
| Allen, J; Chacko-Mathew, J; Gardner, S; Harter, D; Karajannis, M; Kunnakkat, S; Narayana, A; Raza, S; Weiner, H; Wisoff, J | 1 |
| Broholm, H; Hansen, S; Hasselbalch, B; Holmberg, M; Kosteljanetz, M; Lassen, U; Poulsen, HS; Stockhausen, MT; Sørensen, M | 1 |
| Chen, TC; Ghandi, A; Hofman, FM; Liebes, L; Louie, SG; Schönthal, AH; Wang, W | 1 |
| Boyett, JM; Chi, SN; Friedman, HS; Gilbertson, RJ; Gururangan, S; Kun, LE; Onar-Thomas, A; Packer, RJ; Rood, BN; Vajapeyam, S; Young Poussaint, T | 1 |
| Ebi, N; Goto, I; Imamura, F; Iwamoto, Y; Kobayashi, M; Matsui, K; Nakagawa, K; Oizumi, S; Saito, H; Saka, H; Sawa, T; Seki, N; Shibata, K; Takeda, K | 1 |
| Bankiewicz, KS; Berger, MS; Bringas, JR; Dickinson, PJ; Drummond, DC; Forsayeth, J; Higgins, RJ; Kirpotin, DB; Krauze, MT; Larson, RF; LeCouteur, RA; Noble, CO; Park, JW; Yamashita, Y | 1 |
| Chen, J; Lu, Y; Wolff, JE; Xu, T | 1 |
| Broholm, H; Christensen, IJ; Eriksen, JG; Grunnet, K; Hasselbalch, B; Horsman, MR; Lassen, U; Poulsen, HS; Stockhausen, MT | 1 |
| Gizewski, ER; Lanzman, RS; Mathys, C; Mödder, U; Rapp, M; Ringelstein, A; Sabel, M; Saleh, A; Schroeteler, J; Turowski, B | 1 |
| Dosa, E; Kraemer, DF; Neuwelt, EA; Thompson, EM | 1 |
| Almubarak, M; Altaha, R; Khan, M; Nagaiah, G | 1 |
| Chen, C; Damek, D; Fields, EC; Gaspar, LE; Kavanagh, BD; Lillehei, K; Liu, AK; Waziri, A | 1 |
| Bailey, L; Desjardins, A; Friedman, A; Friedman, HS; Herndon, JE; Kirkpatrick, JP; Marcello, J; Peters, KB; Reardon, DA; Sampson, J; Threatt, S; Vredenburgh, JJ | 1 |
| Goebel, G; Gotwald, T; Güler, O; Hutterer, M; Kostron, H; Nowosielski, M; Recheis, W; Schocke, M; Stockhammer, G; Tinkhauser, G | 1 |
| Dalla Palma, M; Farina, P; Furini, L; Lombardi, G; Manara, R; Nicoletto, O; Pastorelli, D; Rotilio, A; Zagonel, V; Zustovich, F | 1 |
| Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M | 1 |
| Callot, V; Chinot, O; Cozzone, PJ; Fellah, S; Girard, N | 1 |
| Brown, MS; Cloughesy, T; Das, A; Goldin, J; Hambleton, J; Huo, J; Kim, HJ; Paton, VE; Pope, WB; Xia, Q | 1 |
| Hasselbalch, B; Jakobsen, JN; Lassen, U; Poulsen, HS; Stockhausen, MT | 1 |
| Anantha, M; Bally, MB; Kozlowski, P; Masin, D; Strutt, D; Verreault, M; Waterhouse, D; Yapp, DT; Yung, A | 1 |
| Dehais, C; Delattre, JY; Golmard, JL; Jouniaux-Delbez, N; Liou, A; Nguyen, BK; Souvannavong, V; Tadrist, C | 1 |
| Coan, A; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Peters, KB; Reardon, DA; Sampson, JH; Threatt, S; Vredenburgh, JJ | 1 |
| Gotwald, T; Hutterer, M; Jacobs, AH; Kostron, H; Muigg, A; Nowosielski, M; Putzer, D; Staffen, W; Stockhammer, G; Tinkhauser, G; Trinka, E; Virgolini, IJ; Waitz, D | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Peters, KB; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Chan, RT; Fung, CF; Hung, KN; Leung, GK; Ng, GK; Pu, JK | 1 |
| Chen, W; Cloughesy, T; Czernin, J; Dahlbom, M; Huang, SC; Phelps, ME; Satyamurthy, N; Schiepers, C; Wardak, M | 1 |
| Brinker, T; Glage, S; Hedrich, HJ; Held, N; Lewis, AL | 1 |
| Cheema, TA; Kanai, R; Kim, GW; Martuza, RL; Passer, B; Rabkin, SD; Wakimoto, H | 1 |
| Bulusu, A; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Peters, KB; Reardon, DA; Sampson, JH; Threatt, S; Vredenburgh, JJ | 1 |
| Anantha, M; Bally, MB; Masin, D; Strutt, D; Verreault, M; Waterhouse, D; Yapp, DT | 1 |
| Fourcade, S; Gaudy-Marqueste, C; Grob, JJ; Richard, MA; Tasei, AM | 1 |
| Brem, S; Chinnaiyan, P; Chowdhary, S; Kahali, S; Murtagh, R; Pan, E; Potthast, L; Prabhu, A; Rojiani, A; Sarcar, B; Tsai, YY; Yu, HM | 1 |
| Bedekar, DP; Donohoe, DL; Kurpad, SN; Pechman, KR; Schmainda, KM | 1 |
| Audrain, O; Carsin, B; Gedouin, D; Hamlat, A; Lecouillard, I; Lesimple, T; Louvel, G; Mesbah, H; Quillien, V; Riffaud, L; Vauleon, E | 1 |
| Cho, YJ; Duk Lee, J; Go, SI; Hwang, YS; Jeong, YY; Kim, DC; Kim, HC; Ko, GH; Lee, GW; Lee, JH; Lee, JS; Oh, S; Yang, JW | 1 |
| Baltes, S; Brinker, T; Geigle, P; Glage, S; Lewis, AL; Mertens, P | 1 |
| Aerts, I; André, N; Bourdeaut, F; Corradini, N; Couec, ML; Leblond, P; Marec Bérard, P; Minckes, O; Rialland, X; Thebaud, E | 1 |
| Barrie, M; Bequet-Boucard, C; Chinot, O; Colavolpe, C; Figarella-Branger, D; Guedj, E; Mancini, J; Metellus, P; Mundler, O; Tabouret, E | 1 |
| Carrillo, JA; Munoz, CA | 1 |
| Chun, C; Kim, B; Kim, JI; Lee, SH; Song, SC | 1 |
| Delattre, JY; Gállego Pérez-Larraya, J; González-Aguilar, A; Guillevin, R; Hoang-Xuan, K; Houillier, C; Lahutte, M; Petrirena, G; Reyes-Botero, G; Sanson, M | 1 |
| Bellanger, A; Hassani, L; Hassani, Y; Hochart, C; Taillibert, S; Xuan, KH | 1 |
| Grunnet, K; Hansen, S; Holmberg, M; Lassen, U; Møller, S; Poulsen, HS; Schultz, H; Sorensen, M | 1 |
| Bassam, A; Nagy, KA; Pikó, B; Puskásné Szatmári, K; Török, E; Vághy, R; Vargáné Tamás, R | 1 |
| Boyett, JM; Fangusaro, J; Friedman, HS; Gajjar, A; Gilbertson, RJ; Goldman, S; Gururangan, S; Kun, LE; McLendon, R; Onar-Thomas, A; Packer, RJ; Vajapeyam, S; Young Poussaint, T | 1 |
| Marutsuka, K; Moritake, H; Nunoi, H; Shimonodan, H; Takeshima, H; Yamada, A; Yokogami, K | 1 |
| Huang, S; Wang, Z; Zhang, G | 1 |
| Happold, C; Hundsberger, T; Seystahl, K; Weller, M; Wick, A; Wick, W; Wiestler, B | 1 |
| Bankiewicz, K; Berger, MS; Butowski, N; Chen, PY; Drummond, DC; Fitzgerald, JB; Forsayeth, JR; James, CD; Kalra, A; Kirpotin, DB; Ozawa, T; Prados, MD; Wei, KC | 1 |
| Aguilera, D; Castellino, RC; Fangusaro, J; Hayes, LL; Kim, S; MacDonald, TJ; Mazewski, C; McNall-Knapp, RY | 1 |
| Bowers, DC; Chintagumpala, MM; Crews, KR; Fouladi, M; Gajjar, A; Heideman, RL; Houghton, PJ; Jones-Wallace, D; Stewart, CF; Thompson, SJ | 1 |
| Kuhn, JG | 1 |
| Cheshire, P; Dodds, HM; Hanna, S; Houghton, P; Rivory, LP; Stewart, CF; Tobin, PJ | 1 |
| Armand, JP; Boige, V; Fabbro, M; Faivre, S; Frenay, M; Germa, C; Raymond, E; Rixe, O; Rodier, JM; Sicard, E; Vassal, G; Vernillet, L | 1 |
| Ames, M; Buckner, JC; Cha, S; Erlichman, C; Kaufmann, SH; Miller, LL; O'Fallon, JR; Reid, JM; Schaaf, LJ; Wright, K | 1 |
| Friedman, HS; Houghton, PJ; Keir, ST | 1 |
| Chen, TC; Fry, D; Liebes, L; Su, S | 1 |
| Bowers, DC; Chintagumpala, MM; Crews, KR; Gajjar, A; Jones-Wallace, D; Stewart, CF | 1 |
| Cloughesy, TF; Elfring, GL; Filka, E; Friedman, H; Kabbinavar, F; Kuhn, J; Miller, LL; Nelson, G | 1 |
| Batchelor, T; Fisher, JD; Gilbert, MR; Grossman, S; Lesser, G; Piantadosi, S; Supko, JG | 1 |
| Bamberg, M; Belka, C; Jendrossek, V | 1 |
| Ikeda, H; Kuroiwa, M; Shitara, T; Tsuchida, Y | 1 |
| Batchelor, TT; Carson, KA; Gilbert, MR; Grossman, SA; Lesser, GJ; Mikkelsen, T; Nabors, LB; Phuphanich, S; Supko, JG | 1 |
| Chang, SM; Cloughesy, TF; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schiff, D; Wen, PY; Yung, WK | 1 |
| Cloughesy, T; Filka, E; Fruehauf, JP; Mehta, R; Parker, RJ | 1 |
| Lobrinus, JA; Matzinger, O; Michielin, O; Périard, D; Stupp, R; Udry, E | 1 |
| Brem, H; Moriarity, JL; Renard, VM; Storm, PB; Tyler, B; Weingart, JD; Wilentz, RE | 1 |
| D'Haene, N; Darro, F; Gaussin, JF; Kiss, R; Mathieu, A; Penant, S; Remmelink, M; Salmon, I; Van Ginckel, R | 1 |
| Billups, C; Bjornsti, MA; Houghton, PJ; Liang, H; Peterson, JK; Woo, MH | 1 |
| Badruddoja, M; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Quinn, JA; Reardon, DA; Rich, JN; Vredenburgh, J | 1 |
| Amistà, P; Basso, U; Brandes, AA; Ermani, M; Monfardini, S; Nicolardi, L; Reni, M; Sotti, G; Tosoni, A; Valduga, F | 1 |
| Chen, A; Chou, R; Lau, D | 1 |
| Bouzourene, H; Chaubert, P; Sandmeier, D | 1 |
| Bamias, A; Briasoulis, E; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Kosmidis, P; Makatsoris, T; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Liang, H | 2 |
| Chiocca, EA; Danks, MK; Finkelstein, DM; Hyatt, JL; Leroy, S; Potter, PM; Saeki, Y; Terada, K; Tyminski, E | 1 |
| Badruddoja, M; Burkart, JL; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, R; Newton, HB; Provenzale, J; Quinn, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, J | 1 |
| Bowers, DC; Broniscer, A; Chintagumpala, M; Fouladi, M; Gajjar, A; Houghton, PJ; Iacono, LC; Kocak, M; Krasin, MJ; Kun, LE; Ledet, D; Merchant, TE; Stewart, CF | 1 |
| Bernshausen, A; Bieler, A; Dravits, T; Gansbacher, B; Glockzin, G; Holm, PS; Köhler-Vargas, N; Lage, H; Mantwill, K | 1 |
| Hegi, ME; Stupp, R; van den Bent, MJ | 1 |
| Alemany, R; Alonso, MM; Bekele, BN; Curiel, DT; Fueyo, J; Gomez-Manzano, C; Jiang, H; Lang, FF; McCormick, F; Yung, WK; Zhou, X | 1 |
| Duncan, J; McLeod, HL; Scheffer, GL; Scheper, RJ; Shannon, WD; Zhang, W | 1 |
| Bankiewicz, KS; Berger, MS; Drummond, DC; Kirpotin, DB; Krauze, MT; Noble, CO; Park, JW; Saito, R; Yamashita, Y | 1 |
| Chang, S; Cloughesy, T; Fine, HA; Fink, K; Greenberg, H; Hess, K; Jaeckle, K; Junck, L; Kuhn, J; Lamborn, K; Mehta, M; Nicholas, MK; Prados, MD; Robins, HI; Schiff, D; Wen, PY; Yung, WK | 1 |
| Chamberlain, MC; Groshen, S; Tsao-Wei, DD | 1 |
| Allegrini, G; Amatori, F; Bocci, G; Cerri, E; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Marcucci, L; Masi, G | 1 |
| Anai, H; Anegawa, G; Honda, M; Kai, T; Kaneko, S; Masuda, T; Nakamura, Y; Ohta, R; Saeki, H; Yokoyama, S | 1 |
| Barger, G; Brem, H; Brem, S; Fruehauf, JP; Huang, W; Parker, R; Sloan, A | 1 |
| Feun, LG; Heros, D; Herrera, C; Landy, H; Marini, A; Markoe, A; Robles, C; Savaraj, N | 1 |
| Azuma, Y; Hayashi, N; Koshiishi, H; Koshiishi, Y; Ohtsubo, Y; Okamura, T; Takahashi, E; Takahashi, M; Tamamoto, F | 1 |
| Bigner, DD; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Quinn, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ; Wagner, M | 1 |
| Choong, NW; Hoffman, PC; Kozloff, M; Mauer, AM; Rudin, CM; Sciortino, DF; Szeto, L; Villano, JL; Vokes, EE; Wade, JL; Winegarden, JD | 1 |
| Mehta, M; Robins, HI; Traynor, AM | 1 |
| Arai, H; Higashida, T; Imada, T; Kanari, M; Masuda, M; Nakayama, T; Rino, Y; Saeki, H; Sekino, Y; Wada, N; Yamada, T; Yukawa, N | 1 |
| Bankiewicz, KS; Drummond, D; Forsayeth, J; Kawaguchi, T; Kirpotin, DB; Krauze, MT; Kullberg, E; Noble, CO; Park, JW; Yamashita, Y | 1 |
| Adamson, PC; Bernstein, M; Blaney, SM; Bomgaars, LR; Chen, Z; Das, S; Kadota, R; Krailo, M | 1 |
| Chen, TC; Hofman, FM; Lee, AS; Pyrko, P; Schönthal, AH | 1 |
| Chen, W; Cloughesy, T; Czernin, J; Delaloye, S; Geist, C; Lai, A; Phelps, ME; Pope, W; Satyamurthy, N; Sayre, J; Silverman, DH | 1 |
| Aldape, KD; Chang, SM; Cloughesy, T; DeAngelis, LM; Fine, H; Fink, KL; Junck, L; Kuhn, J; Lamborn, K; Lieberman, F; Loghin, ME; Metha, M; Prados, MD; Robins, IH; Wen, P; Yung, WK | 1 |
| Cao, Y; Desjardins, A; Dewhirst, MW; Friedman, HS; Herndon, JE; Marcello, JE; McLendon, RE; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Chinen, T; Hirayasu, T; Ishikawa, K; Kawabata, T; Kawasaki, H; Kuniyoshi, M; Ogawa, K; Ohta, M; Oshiro, Y; Samura, H; Teruya, J; Teruya, T; Uehara, T; Yohena, T | 1 |
| Colman, H; Conrad, CA; de Groot, JF; Giglio, P; Gilbert, MR; Groves, MD; Hess, KR; Hsu, SH; Ictech, SE; Jackson, EF; Levin, VA; Mahankali, S; Puduvalli, VK; Ritterhouse, MG; Yung, WK | 1 |
| Ahuja, G; Choudhry, I; Cuellar, S; Setty, S; Villano, JL; Yao, M | 1 |
| Blumenthal, DT; Bokstein, F; Shpigel, S | 1 |
| Blumenthal, DT; Chamberlain, MC; Glantz, MJ; Wei-Tsao, DD | 1 |
| Elinzano, H; Jin, T; Kang, TY; Peereboom, D | 1 |
| Feun, L; Savaraj, N | 1 |
| Chamberlain, MC; Glantz, MJ | 1 |
| Friedman, HS; Malone, S; Petros, WP; Schaaf, LJ; Younis, IR | 1 |
| Fujiwara, T; Matsumoto, Y; Nagao, S | 1 |
| Cheshire, PJ; Danks, MK; Friedman, HS; Hallman, JD; Houghton, JA; Houghton, PJ; Lutz, L | 1 |
| Friedman, HS; Houghton, PJ | 1 |
| Bigner, DD; Elion, GB; Friedman, HS; Hare, CB; Houghton, JA; Houghton, PJ; Keir, S; Marcelli, SL | 1 |
| Bigner, DD; Coggins, CA; Colvin, OM; Elion, GB; Friedman, HS; Hare, CB; Houghton, PJ; Keir, S | 1 |
| Friedman, HS; Furman, WL; Houghton, PJ; Santana, VM; Stewart, CF; Thompson, J | 1 |
| Burton, E; Prados, M | 1 |
| Ashley, D; Bigner, DD; Cloughsey, T; Cokgor, I; Colvin, OM; Elfring, GL; Friedman, AH; Friedman, HS; Haglund, M; Houghton, PJ; Kerby, T; Lawyer, J; Lovell, S; Malczyn, J; McLendon, RE; Miller, LL; Parry, M; Petros, WP; Provenzale, JM; Rasheed, K; Rich, J; Schaaf, LJ; Stewart, ES | 1 |
| Bigner, DD; Castellino, RC; Elion, GB; Friedman, HS; Houghton, PJ; Johnson, SP; Keir, ST | 1 |
| Brent, TP; Cheshire, PJ; Friedman, HS; Houghton, PJ; Kirstein, MN; Poquette, CA; Richmond, LB; Stewart, CF; Tan, M | 1 |
| Fujita, A; Fukuoka, S; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Bigner, DD; Friedman, HS; Hausheer, F; Keir, ST; Lawless, AA | 1 |
| de Bruijn, EA; Dumez, H; Mathijssen, RH; Sparreboom, A; van Oosterom, AT | 1 |
| Beason, R; Bottom, K; Eastwood, J; Friedman, AH; Friedman, HS; Gururangan, S; McLendon, RE; Miller, LL; Tourt-Uhlig, S; Turner, CD; Watral, M | 1 |
| Berg, S; Bernstein, M; Blaney, SM; Cherrick, I; Kuttesch, N; Murry, DJ; Salama, V | 1 |
| Sakai, H; Yoneda, S | 1 |
20 review(s) available for irinotecan and Brain Neoplasms
| Article | Year |
|---|---|
Therapeutic effect and side effects of Bevacizumab combined with Irinotecan in the treatment of paediatric intracranial tumours: Meta-analysis and Systematic Review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Child; Humans; Irinotecan; Survival Rate | 2020 |
An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Dacarbazine; Humans; Irinotecan; Neoplasms; Temozolomide; Vincristine | 2021 |
Anti-angiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Hypertension; Irinotecan; Lomustine; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Progression-Free Survival; Proteinuria; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide | 2018 |
Risk of Adverse Vascular Events in Patients with Malignant Glioma Treated with Bevacizumab Plus Irinotecan: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioma; Humans; Intracranial Thrombosis; Irinotecan; Risk Factors; Topoisomerase I Inhibitors; Treatment Outcome | 2019 |
Antiangiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Hypertension; Irinotecan; Lomustine; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Proteinuria; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide | 2014 |
The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Cancer Vaccines; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; ErbB Receptors; Glioblastoma; Humans; Immunotherapy; Irinotecan; Mice; Temozolomide; Vaccination; Vaccines, Subunit | 2014 |
Experience with irinotecan for the treatment of malignant glioma.
Topics: Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Glioma; Humans; Irinotecan; Topoisomerase I Inhibitors | 2009 |
Antiangiogenic therapy in malignant gliomas.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Disease-Free Survival; Glioma; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Neoplasm Metastasis; Quality of Life; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
[Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Irinotecan; Neovascularization, Pathologic; Temozolomide; Vascular Endothelial Growth Factor A | 2009 |
Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Clinical Trials, Phase II as Topic; Disease-Free Survival; Evidence-Based Medicine; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Recurrence; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carmustine; Drug Implants; Female; Glioblastoma; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Oligodendroglioma | 2010 |
Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Glioblastoma; Humans; Irinotecan; Middle Aged; Recurrence; Survival Analysis | 2011 |
Alternative chemotherapeutic agents: nitrosoureas, cisplatin, irinotecan.
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Cisplatin; Glioma; Humans; Irinotecan; Nitrosourea Compounds | 2012 |
[Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Disease Progression; Drug Approval; Europe; Glioblastoma; Humans; Hungary; Irinotecan; Magnetic Resonance Imaging; Off-Label Use; Recurrence; Temozolomide; Treatment Outcome | 2012 |
A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult | 2012 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmustine; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Irinotecan; Neoplasm Recurrence, Local; Temozolomide | 2003 |
Novel chemotherapeutic agents for the treatment of glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Camptothecin; Cell Differentiation; Dacarbazine; Drug Delivery Systems; Enzyme Inhibitors; ErbB Receptors; Glioblastoma; Humans; Irinotecan; Matrix Metalloproteinase Inhibitors; Signal Transduction; Temozolomide | 2003 |
Recent developments in the use of chemotherapy in brain tumours.
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Dacarbazine; Glioma; Humans; Irinotecan; Temozolomide | 2006 |
Topoisomerase I inhibitors for the treatment of brain tumors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local; Survival Analysis; Topoisomerase I Inhibitors; Topotecan | 2008 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; Enzyme Inhibitors; Glioma; Humans; Irinotecan; Neovascularization, Pathologic; Oligodendroglioma; Protease Inhibitors; Signal Transduction; Temozolomide; Thalidomide | 1999 |
70 trial(s) available for irinotecan and Brain Neoplasms
| Article | Year |
|---|---|
Cost-Effectiveness Analysis of a Three-Drug Regimen Containing Bevacizumab for the Treatment of Recurrent Pediatric
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cerebellar Neoplasms; Child; Cost-Benefit Analysis; Humans; Irinotecan; Medulloblastoma; Temozolomide | 2022 |
Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
Topics: Administration, Metronomic; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Diarrhea; Drug Delivery Systems; Female; Glioblastoma; Humans; Irinotecan; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Nanostructures; Neutropenia; Temozolomide | 2021 |
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Prognosis; Quality of Life; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2018 |
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Survival Rate; Temozolomide | 2019 |
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Neoplasm Grading; Temozolomide; Treatment Outcome | 2013 |
Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cefixime; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Pilot Projects; Sarcoma, Ewing; Temozolomide; Vincristine | 2013 |
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Choline; Creatine; Dacarbazine; Feasibility Studies; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Prognosis; Prospective Studies; Survival Rate; Temozolomide | 2013 |
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Contrast Media; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Imaging, Three-Dimensional; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2013 |
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Fatigue; Hemorrhage; Humans; Hypertension; Infant; Injections, Intravenous; Irinotecan; Neoplasm Recurrence, Local; Proteinuria; Young Adult | 2013 |
Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Temozolomide; Treatment Outcome | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Temozolomide | 2014 |
An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Retrospective Studies; Transcriptome | 2014 |
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Survival Analysis; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2014 |
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Cerebral Cortex; Contrast Media; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Temozolomide; Treatment Outcome; Young Adult | 2015 |
Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carbamazepine; Drug Interactions; Enzyme Induction; Female; Glioma; Glucuronates; Humans; Irinotecan; Male; Middle Aged; Phenobarbital; Phenytoin | 2015 |
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Temozolomide; Treatment Outcome | 2015 |
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2016 |
Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Prognosis; Psychometrics; Quality of Life; Temozolomide | 2016 |
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Contrast Media; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Molecular Imaging; Necrosis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Tumor Burden | 2017 |
Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2008 |
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2009 |
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cohort Studies; Disease-Free Survival; DNA Topoisomerases, Type I; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Recurrence; Survival Analysis | 2008 |
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies | 2009 |
Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Area Under Curve; Brain Neoplasms; Camptothecin; Drug Interactions; Female; Glioma; Glucuronides; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local | 2009 |
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Disease-Free Survival; Female; Glioma; Guanine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2009 |
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Survival Rate; Temozolomide; Treatment Outcome | 2009 |
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Drug Administration Schedule; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult | 2009 |
Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Carmustine; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Radiotherapy; Statistics as Topic; Time Factors; Young Adult | 2010 |
Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carboplatin; Disease Progression; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Treatment Outcome | 2011 |
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cetuximab; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Temozolomide; Young Adult | 2010 |
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Brain Stem Neoplasms; Camptothecin; Child; Diffusion Magnetic Resonance Imaging; Glioma; Humans; Irinotecan; Neoplasm Recurrence, Local; Phosphorylation; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2010 |
Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Dexamethasone; Drug Administration Schedule; Female; Glioma; Glucocorticoids; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide; Tumor Burden; Vincristine; Young Adult | 2012 |
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Craniotomy; Dacarbazine; Dexamethasone; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioblastoma; Glucocorticoids; Humans; Injections, Intravenous; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide; Tumor Burden; Young Adult | 2012 |
Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local | 2011 |
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local | 2011 |
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioma; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib; Young Adult | 2011 |
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2012 |
Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioblastoma; Humans; Hydroxamic Acids; Insulin-Like Growth Factor Binding Protein 5; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Platelet-Derived Growth Factor; Proteomics; Vorinostat | 2012 |
A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Standard of Care; Survival Rate; Young Adult | 2012 |
Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Disease-Free Survival; Ependymoma; Female; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Male; Neoplasm Recurrence, Local; Salvage Therapy; Young Adult | 2012 |
Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Enzyme Induction; Enzyme Inhibitors; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Topoisomerase I Inhibitors | 2002 |
Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.
Topics: Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carbamazepine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Multidrug Resistance-Associated Protein 2; Phenytoin; Probability; Prognosis; Survival Rate; Treatment Outcome | 2002 |
Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Gastrointestinal Diseases; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oligodendroglioma; Polypharmacy; Prospective Studies; Salvage Therapy | 2002 |
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Treatment Outcome; Vomiting | 2003 |
Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Recurrence; Time Factors | 2003 |
Current treatment and future directions in neuroblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Endostatins; Humans; Infant; Irinotecan; Neoplasm Staging; Neuroblastoma; Prospective Studies; Survival Rate | 2003 |
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.
Topics: Adult; Brain Neoplasms; Camptothecin; Confidence Intervals; Drug Administration Schedule; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate | 2004 |
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Brain Neoplasms; Camptothecin; Dose-Response Relationship, Drug; Female; Glioma; Humans; Irinotecan; Linear Models; Male; Middle Aged; Neoplasm Recurrence, Local; North America; Statistics, Nonparametric | 2004 |
A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease Progression; Drug Resistance, Neoplasm; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Predictive Value of Tests; Prospective Studies; Sensitivity and Specificity; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2004 |
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Brain Neoplasms; Camptothecin; Celecoxib; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glioma; Humans; Infusions, Intravenous; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Pyrazoles; Risk Assessment; Statistics, Nonparametric; Sulfonamides; Survival Analysis; Treatment Outcome | 2005 |
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Electroencephalography; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Italy; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome | 2004 |
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis | 2005 |
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome | 2005 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Survival Analysis; Temozolomide; Treatment Outcome | 2006 |
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease-Free Survival; Epilepsy; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome | 2006 |
Salvage chemotherapy with CPT-11 for recurrent meningioma.
Topics: Aged; Agranulocytosis; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Male; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Treatment Failure | 2006 |
Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Diarrhea; Disorders of Excessive Somnolence; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Thalidomide; Treatment Outcome | 2006 |
Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Etoposide; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Teniposide; Tomography, X-Ray Computed | 2007 |
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies | 2007 |
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Disease-Free Survival; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Temozolomide | 2006 |
Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Female; Glucuronosyltransferase; Hepatoblastoma; Humans; Infant; Irinotecan; Male; Medulloblastoma; Neoplasms; Treatment Outcome | 2007 |
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Drug Administration Schedule; Drug Interactions; Enzyme Induction; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2007 |
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Female; Humans; Hypoxia; Irinotecan; Male; Middle Aged; Neovascularization, Pathologic; Proportional Hazards Models; Radiography; Retrospective Studies; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Thalidomide | 2008 |
Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Camptothecin; Dacarbazine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Temozolomide | 2008 |
CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Chromosome Deletion; Chromosomes, Human, Pair 1; Dacarbazine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Survival Analysis; Temozolomide | 2008 |
Irinotecan therapy in adults with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Camptothecin; Disease Progression; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma | 1999 |
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Ependymoma; Female; Glioblastoma; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Medulloblastoma; Topoisomerase Inhibitors | 2002 |
158 other study(ies) available for irinotecan and Brain Neoplasms
| Article | Year |
|---|---|
Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Glioma; Humans; Irinotecan; Neoplasm Grading; Radiosurgery; Retrospective Studies; Treatment Failure; Treatment Outcome | 2022 |
The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Glioma; Humans; Infant; Irinotecan; Neoplasm Recurrence, Local; Retrospective Studies; Young Adult | 2022 |
Antitumor activity of irinotecan with ellagic acid in C6 glioma cells.
Topics: Animals; Brain Neoplasms; Cadherins; Ellagic Acid; Glioma; Irinotecan; Rats; Vascular Endothelial Growth Factor A | 2022 |
Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Glioma; Humans; Irinotecan; Neoplasm Recurrence, Local; Pneumonia, Aspiration; Temozolomide | 2022 |
Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.
Topics: Angiogenesis Inhibitors; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Neoplasm Recurrence, Local | 2023 |
Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local | 2023 |
Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme.
Topics: Animals; Brain Neoplasms; Glioblastoma; Humans; Irinotecan; Mice; Pharmaceutical Preparations; Temozolomide | 2020 |
Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Edema; Brain Neoplasms; Female; Glioma; Irinotecan; Magnetic Resonance Imaging; Male; Microbubbles; Pilot Projects; Prodrugs; Purpura; Random Allocation; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Sonication; Topoisomerase I Inhibitors | 2020 |
Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Disease-Free Survival; Glioblastoma; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Prognosis; Temozolomide; Vincristine | 2021 |
Metronomic Maintenance With Weekly Vinblastine After Induction With Bevacizumab-Irinotecan in Children With Low-grade Glioma Prevents Early Relapse.
Topics: Administration, Metronomic; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Child; Child, Preschool; Female; Glioma; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Retrospective Studies; Vinblastine | 2021 |
Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Brain Neoplasms; Cell Line, Tumor; Female; Glioma; Humans; Irinotecan; Mice; Mice, Nude; Nitro Compounds; Temozolomide; Xenograft Model Antitumor Assays | 2021 |
Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Liberation; Drug Resistance, Neoplasm; Glioblastoma; Humans; Irinotecan; Mice; Microplastics; Microscopy, Electron, Scanning; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Temozolomide; Xenograft Model Antitumor Assays | 2021 |
Neobavaisoflavone May Modulate the Activity of Topoisomerase Inhibitors towards U-87 MG Cells: An In Vitro Study.
Topics: Antibiotics, Antineoplastic; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Etoposide; Glioblastoma; Glutathione; Humans; Irinotecan; Isoflavones; Plant Extracts; Psoralea; Signal Transduction; Topoisomerase II Inhibitors | 2021 |
Effects of an irinotecan derivative, ZBH‑1208, on the immune system in a mouse model of brain tumor and its antitumor mechanism.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Cyclin B1; Cyclin E; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Gene Expression Regulation, Neoplastic; Germ-Free Life; Immunity, Innate; Irinotecan; Male; Mice; Mice, Inbred ICR; Neoplasm Transplantation; Nuclear Proteins; Protein-Tyrosine Kinases; Signal Transduction; Tumor Suppressor Protein p53 | 2017 |
Evaluation of drug combination for glioblastoma based on an intestine-liver metabolic model on microchip.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Caco-2 Cells; Coculture Techniques; Cyclophosphamide; Dacarbazine; Drug Combinations; Drug Delivery Systems; Glioblastoma; Hep G2 Cells; Humans; Intestinal Absorption; Intestines; Irinotecan; Liver; Models, Biological | 2017 |
Sensitivity to
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Etoposide; Gene Expression Profiling; Glioblastoma; Humans; Irinotecan; Protein Serine-Threonine Kinases; RNA, Messenger | 2017 |
Letter to the Editor. Puzzling posology: was the bevacizumab regimen in recurrent glioblastoma misreported?
Topics: Angiogenesis Inhibitors; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local | 2018 |
Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Female; Humans; Injections, Intravenous; Irinotecan; Liposomes; Mice; Mice, Nude; Nanoparticles; Permeability; Tissue Distribution; Topoisomerase I Inhibitors; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Apatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer: Case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Edema; Brain Neoplasms; Camptothecin; Disease Progression; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Oxonic Acid; Pyridines; Tegafur; Triple Negative Breast Neoplasms | 2018 |
Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas?
Topics: Blood-Brain Barrier; Brain Neoplasms; Glioma; Humans; Irinotecan; Neoplasm Grading; Topoisomerase I Inhibitors; Treatment Outcome | 2018 |
Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Female; Irinotecan; Male; MAP Kinase Kinase Kinases; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasm Transplantation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Random Allocation; Temozolomide | 2018 |
A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cost of Illness; Databases, Factual; Female; Glioblastoma; Health Care Costs; Hospitalization; Humans; Irinotecan; Lomustine; Male; Middle Aged; Prognosis; Retrospective Studies; Temozolomide; Time Factors; United States; Young Adult | 2019 |
Localized skin necrosis by bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Drug Eruptions; Humans; Irinotecan; Male; Middle Aged; Necrosis; Skin | 2013 |
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Quality of Life; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Young Adult | 2013 |
Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive, Peripheral; Radiotherapy; Retrospective Studies; Salvage Therapy; Vincristine; Young Adult | 2013 |
Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Glioblastoma; Humans; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Steroids; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Camptothecin; Cost-Benefit Analysis; Decision Trees; Disease-Free Survival; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Monte Carlo Method; Neoplasm Grading; Positron-Emission Tomography; Recurrence; Treatment Outcome; Tyrosine | 2013 |
FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
Topics: Adult; Analysis of Variance; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Female; Germany; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
[An elderly patient with large cell neuroendocrine carcinoma(LCNEC)for whom chemotherapy with irinotecan and split-dose cisplatin(CDDP)proved very effective].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Humans; Irinotecan; Male | 2013 |
Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
Topics: Adenoviridae; Animals; Biotransformation; Brain Neoplasms; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Line, Tumor; Dose-Response Relationship, Drug; Feasibility Studies; Genetic Vectors; Glioma; Humans; Irinotecan; Mice; Mice, Knockout; Mice, SCID; Neural Stem Cells; Rabbits; Time Factors; Tissue Distribution; Topoisomerase I Inhibitors; Transduction, Genetic; Transfection; Xenograft Model Antitumor Assays | 2013 |
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Female; Follow-Up Studies; Glioma; Humans; Immunoenzyme Techniques; Infant; Irinotecan; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Survival Rate | 2014 |
Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Cancer Vaccines; Child; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Doxorubicin; Drug Evaluation; Fatal Outcome; Ganglioglioma; Humans; Immunotherapy; Indoles; Infant; Irinotecan; Male; Mutation, Missense; Neoplasm Proteins; Point Mutation; Polyethylene Glycols; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Salvage Therapy; Sulfonamides; Temozolomide; Thalamus; Treatment Outcome; Vemurafenib | 2014 |
Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Disease-Free Survival; Dose-Response Relationship, Drug; Down-Regulation; Drug Approval; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neoplastic Stem Cells; Quinolines; Spheroids, Cellular; United States; United States Food and Drug Administration; Xenograft Model Antitumor Assays | 2014 |
Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Irinotecan; Liposomes; Nanostructures; Rats | 2014 |
¹⁸F-FLT and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Camptothecin; Data Interpretation, Statistical; Dideoxynucleosides; Dihydroxyphenylalanine; Female; Glioma; Humans; Irinotecan; Kinetics; Male; Middle Aged; Models, Biological; Positron-Emission Tomography; Radiopharmaceuticals; Recurrence; Tissue Distribution | 2014 |
Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Perfusion Imaging; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Camptothecin; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Dacarbazine; Disease Progression; Drugs, Chinese Herbal; Female; Glioblastoma; Herb-Drug Interactions; Humans; Irinotecan; Liver; Middle Aged; Phytotherapy; Temozolomide | 2014 |
Bevacizumab as secondline treatment of glioblastoma - worth the effort?
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Irinotecan; Middle Aged; Radiation-Sensitizing Agents; Retrospective Studies; Temozolomide; Vascular Endothelial Growth Factor A | 2014 |
The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Female; Glioblastoma; Heterografts; Humans; Irinotecan; Mice, Nude; Neuroimaging; Positron-Emission Tomography; Tyrosine | 2014 |
HPLC analysis and extraction method of SN-38 in brain tumor model after injected by polymeric drug delivery system.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Chromatography, High Pressure Liquid; Disease Models, Animal; Drug Delivery Systems; Irinotecan; Mice, Nude; Polymers | 2014 |
RIST: a potent new combination therapy for glioblastoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Child; Dacarbazine; Female; Glioblastoma; Humans; Indoles; Irinotecan; Male; Membrane Potential, Mitochondrial; Mice, Inbred NOD; Molecular Targeted Therapy; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Disease Progression; Female; Glioma; Humans; Irinotecan; Male; Neoplasm Grading; Retrospective Studies; Young Adult | 2015 |
A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Capecitabine; Carboplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab | 2014 |
Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Magnetic Resonance Imaging; Middle Aged; Pelvic Bones; Positron-Emission Tomography; Recurrence; Taxoids; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Long-term efficacy of bevacizumab and irinotecan in recurrent pediatric glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Child, Preschool; Drug Therapy, Combination; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Prodrugs; Time Factors; Tomography, X-Ray Computed | 2015 |
Combination Therapy of Intraperitoneal Rapamycin and Convection- Enhanced Delivery of Nanoliposomal CPT-11 in Rodent Orthotopic Brain Tumor Xenografts.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Drug Monitoring; Glioblastoma; Humans; Infusions, Parenteral; Irinotecan; Liposomes; Rats; Sirolimus; Topoisomerase I Inhibitors; TOR Serine-Threonine Kinases; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Drug Delivery Systems; Drug Therapy, Combination; Glioma; Humans; Irinotecan; Mice; Platelet Endothelial Cell Adhesion Molecule-1; Time Factors; Xenograft Model Antitumor Assays | 2015 |
Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Temozolomide; Tissue Distribution | 2015 |
Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retreatment; Retrospective Studies; Salvage Therapy | 2015 |
Antitumor efficacy and intratumoral distribution of SN-38 from polymeric depots in brain tumor model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Concurrent delivery of carmustine, irinotecan, and cisplatin to the cerebral cavity using biodegradable nanofibers: In vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Camptothecin; Carmustine; Cisplatin; Glioblastoma; In Vitro Techniques; Irinotecan; Nanofibers; Rats; Rats, Wistar | 2015 |
Second-Line Chemotherapy in Recurrent Glioblastoma: A 2-Cohort Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Female; Glioblastoma; Humans; Irinotecan; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Portugal; Prevalence; Procarbazine; Retrospective Studies; Risk Assessment; Survival Analysis; Survival Rate; Treatment Outcome; Vincristine | 2015 |
Convection-enhanced delivery of SN-38-loaded polymeric micelles (NK012) enables consistent distribution of SN-38 and is effective against rodent intracranial brain tumor models.
Topics: Animals; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Convection; Drug Delivery Systems; Gadolinium; Glioma; Humans; Irinotecan; Male; Mice; Micelles; Polymers; Rats; Rats, Inbred F344; Rats, Nude | 2016 |
Long-term survival in small-cell carcinoma of the endometrium with liver and brain metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Endometrial Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms | 2016 |
Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Neurosurgical Procedures; Prognosis; Survival Analysis; Temozolomide | 2016 |
NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain; Brain Neoplasms; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Drug Monitoring; Female; Humans; Irinotecan; Luminescent Measurements; Mice; Molecular Structure; Permeability; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Dacarbazine; Drug Administration Schedule; Drug Compounding; Glioblastoma; Humans; Irinotecan; Liposomes; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Temozolomide; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway | 2015 |
The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Cyclophosphamide; Dacarbazine; Glioblastoma; Humans; Irinotecan; Lomustine; Neoplasm Grading; Neoplasm Recurrence, Local; Oligodendroglioma; Procarbazine; Radiotherapy; Singapore; Temozolomide; Teniposide; Vincristine | 2015 |
Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Models, Biological; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Young Adult | 2016 |
Long-term exposure to irinotecan reduces cell migration in glioma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Brain Neoplasms; Camptothecin; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Glioma; Humans; Irinotecan; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay; Wound Healing | 2016 |
Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Drug Therapy, Combination; Female; Glioblastoma; Humans; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Radiosurgery; Radiotherapy, Adjuvant; Re-Irradiation; Retrospective Studies; Temozolomide | 2016 |
OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Topics: Acetanilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Everolimus; Gene Expression Regulation, Neoplastic; Glioblastoma; Heterocyclic Compounds, 3-Ring; Humans; Irinotecan; Mice; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Brain; Brain Neoplasms; Camptothecin; Cisplatin; Disease Models, Animal; Drug Delivery Systems; Ethylnitrosourea; Glioblastoma; Glioma; Humans; Irinotecan; Lactic Acid; Male; Nanofibers; Neurosurgical Procedures; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Tumor Burden | 2016 |
Injectable SN-38-loaded Polymeric Depots for Cancer Chemotherapy of Glioblastoma Multiforme.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Delivery Systems; Drug Liberation; Female; Glioblastoma; Heterografts; Humans; Injections; Irinotecan; Mice, Inbred BALB C; Mice, Nude; Polyesters; Polyethylene Glycols | 2016 |
Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Retrospective Studies | 2017 |
[A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Radiography | 2008 |
Bortezomib as a therapeutic candidate for neuroblastoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Brain Neoplasms; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Genes, p53; Humans; Irinotecan; Neuroblastoma; NF-kappa B; Pyrazines | 2008 |
Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Glioma; Humans; Infant; Irinotecan; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Prospective Studies; Treatment Outcome | 2009 |
Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Cerebral Hemorrhage; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Genetic Testing; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Patient Compliance; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2009 |
The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Models, Theoretical; Radiosurgery; Regression Analysis; Statistics as Topic; Temozolomide; Tumor Burden | 2009 |
Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Diffusion Magnetic Resonance Imaging; Glioblastoma; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Young Adult | 2010 |
Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chromosomes, Human, Pair 1; Genetic Predisposition to Disease; Genotype; Humans; Irinotecan; Mutation; Neoplasm Recurrence, Local; Oligodendroglioma; Survival Rate; Treatment Outcome | 2010 |
Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cell Proliferation; Glioma; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Irinotecan; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Polymers; Xenograft Model Antitumor Assays | 2010 |
Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplasms; Camptothecin; Cell Proliferation; Comet Assay; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Drug Synergism; Fluorescent Antibody Technique; Glioblastoma; Humans; Hydroxamic Acids; Irinotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vorinostat | 2010 |
Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Withholding Treatment | 2010 |
Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Disease Models, Animal; Doxorubicin; Drug Carriers; Drug Delivery Systems; Female; Glioma; Injections, Intralesional; Irinotecan; Male; Microspheres; Pilot Projects; Rats; Survival Analysis | 2010 |
[Clinical features of patients with brain metastasis from testicular germ cell tumor].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Retrospective Studies; Testicular Neoplasms; Treatment Outcome | 2010 |
Bevacizumab in recurrent high-grade pediatric gliomas.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Young Adult | 2010 |
Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Implants; Glioma; Humans; Irinotecan; Mice; Mice, Nude; Survival Analysis; Tissue Distribution | 2011 |
Canine spontaneous glioma: a translational model system for convection-enhanced delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Convection; Disease Models, Animal; Dogs; Drug Delivery Systems; Glioma; Irinotecan; Liposomes; Magnetic Resonance Imaging; Nanoparticles | 2010 |
Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers; Brain Neoplasms; Camptothecin; Cell Hypoxia; Cetuximab; Drug Therapy, Combination; ErbB Receptors; Female; Glioblastoma; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Prospective Studies | 2010 |
[Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain; Brain Neoplasms; Camptothecin; Contrast Media; Diffusion Magnetic Resonance Imaging; Female; Follow-Up Studies; Gadolinium; Glioblastoma; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Irinotecan; Male; Neoplasm Recurrence, Local; Sensitivity and Specificity; Vascular Endothelial Growth Factor A | 2010 |
Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide | 2011 |
ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Diffusion Magnetic Resonance Imaging; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Middle Aged; Prognosis; Recurrence; Retrospective Studies; Treatment Outcome | 2011 |
Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Glioblastoma; Humans; Irinotecan; Retrospective Studies; Treatment Outcome | 2010 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine | 2011 |
Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Fatal Outcome; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Angiography; Male; Neoplasm Recurrence, Local; Spin Labels | 2011 |
Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Capillary Permeability; Cell Line, Tumor; Chemistry, Pharmaceutical; DNA-Binding Proteins; Doxorubicin; Glioblastoma; Humans; Injections, Intravenous; Irinotecan; Liposomes; Mice; Mice, Knockout; Nanoparticles; Tumor Burden; Vincristine; Xenograft Model Antitumor Assays | 2011 |
[An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumab].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Diagnostic Self Evaluation; Fatigue; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Recurrence; Surveys and Questionnaires | 2011 |
O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Female; Glioma; Humans; Image Processing, Computer-Assisted; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Nervous System Diseases; Positron-Emission Tomography; Postoperative Complications; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Treatment Failure; Tyrosine; Ultrasonography | 2011 |
Using bevacizumab in the fight against malignant glioma: first results in Asian patients.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Asian People; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies | 2011 |
Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dideoxynucleosides; Discriminant Analysis; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Prognosis; Radionuclide Imaging | 2011 |
A safety and toxicity assessment of the administration of multiple intracerebral injections of irinotecan or doxorubicin drug-eluting beads.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cats; Doxorubicin; Female; Glioma; Infusion Pumps, Implantable; Injections, Intraventricular; Irinotecan; Male; Microspheres; Necrosis; Safety; Treatment Outcome | 2011 |
Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Etoposide; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neural Stem Cells; Oncolytic Virotherapy; Oncolytic Viruses; Simplexvirus; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2011 |
Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Female; Glioblastoma; Humans; Irinotecan; Liposomes; Mice; Nanoparticles; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Localized skin necrosis of steroid-induced striae distensae: an unusual complication of bevacizumab and irinotecan therapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Fatal Outcome; Glioblastoma; Humans; Irinotecan; Male; Methylprednisolone Hemisuccinate; Necrosis; Skin; Striae Distensae | 2011 |
Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Volume; Blood Volume Determination; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cerebrovascular Circulation; Irinotecan; Magnetic Resonance Imaging; Male; Rats; Rats, Nude; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2012 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Drug Therapy, Combination; Glioblastoma; Humans; Irinotecan; Lomustine; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Radiation-Sensitizing Agents; Retrospective Studies; Temozolomide | 2012 |
Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carboplatin; Cisplatin; DNA-Binding Proteins; Endonucleases; Etoposide; Female; Follow-Up Studies; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Evaluation of biocompatibility and anti-glioma efficacy of doxorubicin and irinotecan drug-eluting bead suspensions in alginate.
Topics: Alginates; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Doxorubicin; Drug Delivery Systems; Female; Glioma; Glucuronic Acid; Hexuronic Acids; Irinotecan; Male; Materials Testing; Microspheres; Rats; Survival Rate; Suspensions; Tumor Burden | 2012 |
Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Male; Retrospective Studies | 2012 |
FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Fluorodeoxyglucose F18; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2012 |
MRI-monitored long-term therapeutic hydrogel system for brain tumors without surgical resection.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Female; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Irinotecan; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; NIH 3T3 Cells; Polymers | 2012 |
Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Diagnostic Imaging; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2012 |
[Monitoring and evaluation tools for irinotecan and bevacizumab in glioblastoma: from prescription to patient's information].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Contraindications; Drug Monitoring; Family; France; General Practice; Glioblastoma; Humans; Irinotecan; Medical Oncology; Off-Label Use; Pamphlets; Patient Education as Topic; Pharmaceutical Services; Pharmacovigilance; Prescription Drugs | 2012 |
Efficacy of temozolomide in a central nervous system relapse of neuroblastoma with O 6 -methylguanine methyltransferase (MGMT) promoter methylation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child, Preschool; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Neuroblastoma; Prognosis; Promoter Regions, Genetic; Stem Cell Transplantation; Temozolomide; Transplantation, Autologous; Tumor Suppressor Proteins | 2013 |
Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Drug Therapy, Combination; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2013 |
Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Convection; Drug Administration Routes; Drug Delivery Systems; Female; Glioblastoma; History, Ancient; Humans; Immunoenzyme Techniques; Injections, Intraperitoneal; Irinotecan; Liposomes; Mice; Mice, Nude; Nanoparticles; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Dacarbazine; Drug Administration Schedule; Female; Humans; Infant; Irinotecan; Male; Medulloblastoma; Recurrence; Retrospective Studies; Temozolomide; Treatment Outcome | 2013 |
The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Brain Neoplasms; Camptothecin; Carboxylic Ester Hydrolases; Chromatography, High Pressure Liquid; Female; Glucuronidase; Humans; Irinotecan; Kinetics; Mice; Mice, SCID; Microdialysis; Neoplasm Transplantation; Neuroblastoma; Transplantation, Heterologous | 2002 |
Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group.
Topics: Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Glioblastoma; Glioma; Humans; Irinotecan | 2003 |
Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
Topics: Anthracenes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Camptothecin; Cell Line; Glioblastoma; Humans; Irinotecan; Naphthalenes; Perylene; Protein Kinase C; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Staurosporine; Tamoxifen; Tumor Cells, Cultured | 2003 |
Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Area Under Curve; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Safety | 2003 |
Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Drug Administration Schedule; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Safety; Treatment Outcome | 2003 |
Irinotecan-induced interstitial pneumonia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Diagnosis, Differential; Frontal Lobe; Glioblastoma; Humans; Irinotecan; Lung Diseases, Interstitial; Male; Radiography; Temozolomide | 2004 |
Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
Topics: Animals; Brain Neoplasms; Camptothecin; Carmustine; Cell Line, Tumor; Enzyme Inhibitors; Female; Gliosarcoma; Irinotecan; Neoplasm Transplantation; Rats; Rats, Inbred F344; Topoisomerase I Inhibitors | 2004 |
Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resista
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cyclooxygenase 2; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Intramolecular Oxidoreductases; Irinotecan; Isoenzymes; Liver Neoplasms; Lung Neoplasms; Membrane Proteins; Mice; Mice, Nude; Neoplasm Proteins; Organoplatinum Compounds; Ornithine Decarboxylase; Oxaliplatin; Paclitaxel; Prostaglandin-E Synthases; Prostaglandin-Endoperoxide Synthases; Survival Rate; Transplantation, Heterologous; Vault Ribonucleoprotein Particles | 2004 |
Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Drug Administration Schedule; Female; Irinotecan; Mice; Mice, Inbred ICR; Sesquiterpenes; Treatment Failure; Xenograft Model Antitumor Assays | 2005 |
Complete response of brain metastases to irinotecan-based chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Esophageal Neoplasms; Female; Humans; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Parotid Neoplasms | 2005 |
Irinotecan-induced colitis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers; Biopsy; Brain Neoplasms; Camptothecin; Colitis; Colon; Diarrhea; Glioblastoma; Humans; Ileum; Immunoenzyme Techniques; Irinotecan; Male; Topoisomerase I Inhibitors | 2005 |
Modeling antitumor activity in xenograft tumor treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Computer Simulation; Dacarbazine; Dose-Response Relationship, Drug; Drug Therapy, Computer-Assisted; Irinotecan; Mice; Models, Biological; Models, Statistical; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Brain Neoplasms; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cyclophosphamide; Cytochrome P-450 CYP2B1; Genetic Therapy; Glioma; Herpesvirus 1, Human; Humans; Irinotecan; Prodrugs; Virus Replication | 2005 |
Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Blotting, Southern; Brain Neoplasms; Camptothecin; Coxsackie and Adenovirus Receptor-Like Membrane Protein; Enzyme Inhibitors; Fibroblasts; Gene Deletion; Gene Expression; Gentian Violet; Glioblastoma; HeLa Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunohistochemistry; Irinotecan; Oncolytic Viruses; Protein Synthesis Inhibitors; Receptors, Virus; Tumor Cells, Cultured | 2006 |
Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Brain Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Drug Synergism; Flow Cytometry; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; S Phase; Survival Rate; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
Expression of drug pathway proteins is independent of tumour type.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Lymphoma; Male; Melanoma; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Tissue Array Analysis | 2006 |
Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy.
Topics: Animals; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Convection; Drug Delivery Systems; Humans; Irinotecan; Liposomes; Male; Nanostructures; Phospholipids; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays | 2006 |
Comparison of antitumor activities in tumor xenograft treatment.
Topics: Algorithms; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Disease Models, Animal; Humans; Irinotecan; Mice; Sesquiterpenes; Transplantation, Heterologous; Treatment Outcome | 2007 |
[A case of inoperable gastric small cell carcinoma effectively treated by chemotherapy and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Drug Combinations; Etoposide; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2006 |
In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Carmustine; Cisplatin; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Glutathione S-Transferase pi; Humans; Immunohistochemistry; Irinotecan; Paclitaxel; Structure-Activity Relationship; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vincristine | 2006 |
[Evaluation of bronchial arterial infusion (BAI) for lung cancer with brain metastasis].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Bronchial Arteries; Camptothecin; Cisplatin; Female; Humans; Infusions, Intra-Arterial; Irinotecan; Lung Neoplasms; Male; Middle Aged; Quality of Life | 2006 |
Temozolomide as prophylaxis for brain metastasis in non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Humans; Irinotecan; Lung Neoplasms; Temozolomide | 2006 |
[Irinotecan+cisplatin and irradiation are effective for brain metastases of gastric cancer--two case reports].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Gastrectomy; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Quality of Life; Radiosurgery; Radiotherapy Dosage; Remission Induction; Splenectomy; Stomach Neoplasms | 2007 |
Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Convection; Doxorubicin; Drug Synergism; Half-Life; Humans; Irinotecan; Liposomes; Male; Nanoparticles; Neoplasm Transplantation; Rats; Rats, Sprague-Dawley; Tissue Distribution; Xenograft Model Antitumor Assays | 2007 |
The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Caspase 7; Catechin; Cell Growth Processes; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Fluorouracil; Glioblastoma; Heat-Shock Proteins; Humans; Irinotecan; Molecular Chaperones; RNA, Small Interfering; Temozolomide; Transcription Factor CHOP; Transfection | 2007 |
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cell Proliferation; Female; Fluorine Radioisotopes; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiography; Radiopharmaceuticals; Survival Rate; Thymidine | 2007 |
Bevacizumab plus irinotecan in recurrent glioblastoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local | 2008 |
[A case of long-term survival of postoperative brain metastasis of small cell lung cancer effectively treated with chemotherapy, whole brain radiotherapy and stereotactic radiosurgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Radiosurgery; Time Factors; Tomography, X-Ray Computed | 2008 |
Complete response of CNS-involved olfactory neuroendocrine tumor using multimodal therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cisplatin; Ethmoid Bone; Humans; Irinotecan; Male; Neuroendocrine Tumors; Organization and Administration; Radiotherapy, Adjuvant; Skull Neoplasms | 2008 |
Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate | 2008 |
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cerebral Hemorrhage; Child; Child, Preschool; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Glioma; Humans; Irinotecan; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Brain Neoplasms; Camptothecin; Enterohepatic Circulation; Female; Glioma; Half-Life; Humans; Irinotecan; Male | 2009 |
Determinants of drug response in camptothecin-11-resistant glioma cell lines.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance; Flow Cytometry; Glioma; Glutathione; Glutathione Transferase; Humans; Irinotecan; Nucleic Acid Conformation; Rats; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1995 |
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasms, Experimental; Random Allocation; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
Treatment of central nervous system xenografts with camptothecins.
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Topotecan; Transplantation, Heterologous | 1996 |
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Camptothecin; Carmustine; Child; Cyclophosphamide; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1998 |
Extending principles learned in model systems to clinical trials design.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Models, Biological; Research Design | 1998 |
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carmustine; Drug Synergism; Drug Therapy, Combination; Female; Glioma; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Brain Neoplasms; Camptothecin; Dacarbazine; DNA Repair; Female; Glioblastoma; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neuroblastoma; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Rhabdomyosarcoma; Temozolomide; Time Factors | 2000 |
Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Male; Middle Aged; Radiosurgery; Radiotherapy, Adjuvant; Recombinant Proteins; Retrospective Studies; Survival Analysis; Treatment Outcome | 2000 |
Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Female; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous | 2001 |
Altered irinotecan metabolism in a patient receiving phenytoin.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Drug Interactions; Glioma; Humans; Irinotecan; Phenytoin; Topoisomerase I Inhibitors | 2002 |
Influence of phenytoin on the disposition of irinotecan: a case report.
Topics: Adolescent; Anticonvulsants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Disease Progression; Drug Interactions; Enzyme Induction; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Melphalan; Mixed Function Oxygenases; Neoplasm Recurrence, Local; Ondansetron; Phenobarbital; Phenytoin; Pineal Gland; Pinealoma; Prodrugs; Salvage Therapy; Seizures | 2002 |
[Small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Irinotecan; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Radiotherapy, Adjuvant; Treatment Outcome | 2002 |